Welcome to the Bahria University DSpace digital repository. DSpace is a digital service that collects, preserves, and distributes digital material. Repositories are important tools for preserving an organization's legacy; they facilitate digital preservation and scholarly communication.
dc.contributor.author | Tafazzul Hussain | |
dc.contributor.author | Musarrat Sultana | |
dc.contributor.author | Syeda Amber Zaidi | |
dc.contributor.author | Syed Saud Hasan | |
dc.contributor.author | Mohsin Turab | |
dc.contributor.author | Shamaila Khalid | |
dc.date.accessioned | 2020-02-11T08:42:11Z | |
dc.date.available | 2020-02-11T08:42:11Z | |
dc.date.issued | 2020-01-01 | |
dc.identifier.issn | 2220-7562 | |
dc.identifier.uri | http://hdl.handle.net/123456789/9224 | |
dc.description.abstract | Objective: To determine the effect of Allopurinol & Febuxostat for the treatment of hyperuricemic patients & its influence on renal function by measuring serum creatinine level. Study Design & setting: The clinical trial was conducted at Dr. Ruth K M Pfau Civil Hospital, Karachi, during the period of September 2018 to March 2019 Methodology: 60 patients with sUA > 6.8 mg/dl were registered. A detailed history was taken, patient's baseline serum Uric Acid (sUA) & serum Creatinine were measured. Patients were divided into two groups to receive Allopurinol, 300 mg & Febuxostat 80 mg, daily for 90-days. The blood parameters were repeated at day 30 and 90. Results: Group-A (Allopurinol treated patients) baseline uric acid changed from mean 8.79 ± 0.98 mg/dl to 6.40 ± 0.86 mg/dl at day 90. In Group-B (Febuxostat treated patients) sUA baseline mean changed from 8.85 ± 0.97 mg/dl to 5.96 ± 0.68 mg/dl. Mean difference ± SD change of serum uric acid in Group-A was 2.39 ± 1.15 mg/dl and with Group-B it was 2.90 ± 0.87 mg/dl. Mean Serum Creatinine in Group-A changed from 1.54 ± 0.39 mg/dl to mean 1.48 ± 0.40 mg/dl compared with Group-B where it changed from 1.42 ± 0.30 mg/dl to 1.45 ± 0.31 mg/dl at day-90. Mean difference ± SD of serum Creatinine in Group-A was 0.11 ± 0.25 mg/dl & in Group-B it was, 0.03 ± 0.15 mg/dl. The above changes were statistically non-significant with p-value of 0.144. Conclusion: Allopurinol and Febuxostat treatment resulted in improvement of serum Uric Acid levels while maintaining their renal function. | en_US |
dc.description.sponsorship | JBUMDC | en_US |
dc.language.iso | en | en_US |
dc.publisher | Bahria University Medical and Dental College Karachi | en_US |
dc.relation.ispartofseries | 10;01 | |
dc.subject | Allopurinol, Febuxostat, Serum uric acid, Serum creatinine. | en_US |
dc.title | Comparison of Allopurinol And Febuxostat in Asymptomatic Hyperuricemic Patients and their Impact on Serum Creatinine | en_US |
dc.type | Article | en_US |